Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
Immunomodulator agent indicated for the treatment of patients affected with highly active relapsing remitting multiple sclerosis.
Oral administration once a day for prolonged periods.
Since the last update we have not found any published data on its excretion in breast milk.
Pharmacokinetic data (large volume of distribution and high protein binding capacity) make it very unlikely its passage to breast milk in significant amounts, but its long half-life could allow it.
Although generally contraindicated in lactation (Langer 2019, Alroughani 2016, Cree 2013, Houtchens 2013), other expert authors consider the use of this medication during lactation probably safe (Briggs 2017).
Until there is more published data on this drug in relation to breastfeeding, safer known alternatives may be preferable, especially during the neonatal period and in cases of prematurity.